Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

2.

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R.

Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.

3.

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM.

Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.

PMID:
26193343
4.

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.

Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC.

Blood. 2015 Aug 13;126(7):842-50. doi: 10.1182/blood-2014-12-617522. Epub 2015 Jun 26.

5.

Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.

Furtado M, Wang ML, Munneke B, McGreivy J, Beaupre DM, Rule S.

Br J Haematol. 2015 Jul;170(1):131-4. doi: 10.1111/bjh.13275. Epub 2015 Jan 6. No abstract available.

PMID:
25559624
6.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.

Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, Rowinsky EK, Xu LA, Harbison CT, Clark EA, Mauro DJ, Khambata-Ford S.

Br J Cancer. 2011 Feb 1;104(3):488-95. doi: 10.1038/sj.bjc.6606054. Epub 2011 Jan 4.

7.

Adding confidence to gene expression clustering.

Munneke B, Schlauch KA, Simonsen KL, Beavis WD, Doerge RW.

Genetics. 2005 Aug;170(4):2003-11. Epub 2005 Jun 8.

8.

The Dutch-Belgian beamline at the ESRF.

Borsboom M, Bras W, Cerjak I, Detollenaere D, Glastra Van Loon D, Goedtkindt P, Konijnenburg M, Lassing P, Levine YK, Munneke B, Oversluizen M, Van Tol R, Vlieg E.

J Synchrotron Radiat. 1998 May 1;5(Pt 3):518-20. Epub 1998 May 1.

PMID:
15263564

Supplemental Content

Loading ...
Support Center